Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer

Taizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, Takahiro Kimura, Kazuhiro Takahashi, Kazuki Nishimura, Keita Nakamori, Yuya Fujiwara, Tomohisa Matsunaga, Takeshi Tsutsumi, Takuya Tsujino, Ryoichi Maenosono, Yuki Yoshikawa, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Naokazu Ibuki, Hajime Hirano, Hayahito Nomi, Kiyoshi Takahara, Teruo Inamoto, Shin Egawa and Haruhito Azuma

Abstract: The identification of early or primary resistance to androgen signaling inhibitors (ASIs) is of great value for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the predictive value of prostate-specific antigen (PSA) response at four weeks of first-line ASIs treatment for mCRPC patients. A total of 254 patients treated with ASIs (abiraterone acetate: AA and enzalutamide: Enz) at the first-line treatment are retrospectively analyzed. Patients are stratified according to the achievement of >30% PSA decline at four weeks—an achievement of the >30% PSA decline at 12 weeks is eventually observed in 30.9% of those patients. To identify the variables that discriminate the patient survival in 97 patients without achieving >30% PSA decline at four weeks of the first-line treatment, a multivariate analysis is conducted. The duration of androgen deprivation therapy before CRPC < 12 months and Eastern Cooperative Oncology Group Performance Status ≥ 1 are identified as independent predictors for shorter OS for those patients.
at four weeks, a multivariate analysis is performed. The duration of androgen deprivation therapy before CRPC \( \leq 12 \) months and Eastern Cooperative Oncology Group Performance Status \( \geq 1 \) are identified as independent predictors for shorter OS for those patients. These data offer a concept of early treatment switch after four weeks of first-line ASIs when not observing >30% PSA decline at four weeks—particularly in patients with a modest effect of ADT and poor performance status.

**Keywords:** castration-resistant prostate cancer; androgen signaling inhibitors; abiraterone acetate; enzalutamide; prostate-specific antigen; PSA decline; early PSA

### 1. Introduction

Prostate cancer (PC) is the most common cancer in men, and estimated numbers in the United States account for 31,620 deaths and 174,650 new patients in 2019 [1]. Most PC patients are diagnosed at the local stage, and five years overall survival (OS) rate in those patients reached \( \geq 95\% \) with the established treatment strategy, while patients with distant metastasis declined to that of 30% [2]. Androgen deprivation therapy (ADT) has been a central mainstay of the treatment for advanced PC. Although almost all PC patients initially respond to ADT, acquired resistance has been developed in most patients within a couple of years, namely, castration-resistant PC (CRPC), which leads to the lethal stage through multiple mechanisms [3–7]. In the last decade, several new drugs approved by FDA have emerged with improved clinical outcomes in metastatic CRPC (mCRPC) patients, including androgen signaling inhibitors (ASIs: abiraterone, enzalutamide, and apalutamide), cabazitaxel, and radium-223 [8–13]. Those new agents have innovated on the treatment strategy for mCRPC, which now raises new questions, i.e., the precise treatment sequence and uncovering a reliable marker to predict the treatment outcomes using those drugs for mCRPC patients [14–16].

Prostate-specific antigen (PSA) is widely used for diagnosis and evaluation of treatment effect for PC. It has been well-documented that PSA kinetics from the treatment initiation would serve as a predictive surrogate for OS [17,18]. Most prospective trials have adopted an evaluation of PSA at 12 weeks rather than four weeks of the treatment, due to the possibility of late response and flare reactions, especially when using taxanes [19–21]. Thus, a hypothesis that an early PSA response as early as four weeks of the treatment offers a predictive impact on treatment outcomes is still controversial. Recently, a report from an international study exhibited that >30% PSA decline (PSA30D) at four weeks of the treatment using abiraterone acetate (AA) and enzalutamide (Enz) is strongly associated with OS, whereas their cohort included the population of pre- and post-chemotherapy patients [22]. In the present study, we assessed the predictive value of PSA30D at four weeks focusing on the first-line ASIs treatment.

### 2. Materials and Methods

#### 2.1. Cohorts and Variables

This retrospective study was conducted using multi-institutional cohorts, including Osaka Medical College (Osaka, Japan) and The Jikei University School of Medicine (Tokyo, Japan) with their local satellite hospitals. The design of the study has been approved by the institutional review board of Osaka Medical College (IRB approval number: RIN-750-2571, Date of approval: 24 January 2020) and performed with the consent of the World Medical Association Declaration of Helsinki [23]. As shown in Figure 1, clinical records of consecutive 531 patients were collected, in which 422 (79.5%) patients were diagnosed as mCRPC with any distant metastasis, and 109 (20.5%) patients were assigned to non-metastatic CRPC (nmCRPC) with no distant metastasis at the diagnosis of CRPC. In the present study, we excluded nmCRPC patients from the analysis. Of 422 mCRPC patients, patients were treated with first-line therapy, including abiraterone acetate (AA) (\( n = 134, 31.8\% \)), enzalutamide (Enz) (\( n = 151, 35.8\% \)), and docetaxel (137, 32.4\%). Of the patients...
treated with ASIs at the first-line treatment (AA and Enz), 31 patients experienced treatment failure within 12 weeks or did not have records of serum PSA level at both 4 and 12 weeks. In total, 254 mCRPC patients treated with ASIs (AA and Enz) at the first-line treatment were enrolled in the present study to evaluate clinical outcomes and PSA kinetics.

Clinical variables in the present study involve Age at CRPC (years) (≤70/>70), PSA (ng/ml) at diagnosis, Clinical stage at diagnosis (T2-T3/T4), Gleason sum score at diagnosis (<9/>9), duration of ADT before CRPC (months) (≥12/<12), bone mets at CRPC (−/+), lymph node mets at CRPC (−/+), visceral mets at CRPC (−/+), eastern cooperative oncology group performance status (ECOG-PS) at CRPC (0/>1). The data of blood examination includes PSA at the diagnosis of CRPC, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and hemoglobin (Hb). The PSA value was measured by automated Chemiluminescence Immunoassays (CLIA) (ARCHITECT Total PSA Calibrators 7K70-01, ABBOTT Laboratories) in all participating institutes. Other laboratory data were measured by the methods of enzyme-linked immunosorbent assay (ELISA) (FUJIFILM Toyama Chemical Co. Ltd, Miyazaki 889-1601, Japan; LDH: catalog number 468-76691, ALP: catalog number 464-55791).

2.2. Diagnosis of CRPC, Follow-Up, and Treatments

CRPC was defined according to the PCWG2 guidelines, i.e., serum testosterone level <50 ng/dL with either PSA progression (an increase of 25% and an absolute increase of 2 ng/mL or more above PSA nadir) or radiographic progression [24]. The clinical-stage was evaluated using magnetic resonance imaging (MRI), computed tomography (CT), and bone scintigraphy to examine the number and location of metastasis at the diagnosis of CRPC. Lymph node metastasis was defined with >15 mm according to the RECIST guidelines (version 1.1) [25]. All the other clinical variables, including age, response duration of ADT, Gleason sum score at diagnosis, ECOG-PS, and clinical laboratory measurement in peripheral blood (PSA, ALP, LDH, and Hb), were recorded at the diagnosis of CRPC. ASIs were administrated with a standard dose, i.e., Enz in 160 mg/day [8,10] and AA in 1000 mg plus prednisone 10 mg/day. Dose modification and treatment intervals were considered by side-effects and general conditions with the physician’s discretion. Follow-up CT for detecting any findings suspected of disease progression was scheduled every three months from the diagnosis of CRPC. MRI, bone scintigraphy, and positron emission tomography/computed tomography (PET/CT) were further performed when necessary for the definitive diagnosis of disease progression. The primary endpoints of the study involved OS. The secondary endpoints were time to PSA progression (TTPP), which was defined based on the PCWG2 guidelines (an increase of 25% and an absolute increase of
2 ng/mL or more above the PSA nadir) [24]. OS was calculated from the diagnosis of mCRPC to the last follow-up or death. Serum PSA level was measured every month from the baseline assessment at the initiation of the first-line treatment.

2.3. Statistical Analyses

A Chi-square test was performed to evaluate the distribution of each variable by a contingency table. The student’s t-test was examined to assess the difference between the variables. Kolmogorov-Smirnov normality was conducted to check normal distribution in continuous variables. For variables with non-normal distribution, Wilcoxon or Kruskal-Wallis test was evaluated to examine the difference between the groups. Kaplan-Meier curves were calculated to estimate the survival ratio. The ability for outcome prediction of continuous variables in PSA changes was determined by receiver operating characteristic (ROC) curve analysis, and the optimal cut-off values were defined by the Youden index as the point maximizing the difference between true positive rate and false-positive rate across all possible cut-point values [26,27]. A log-rank test was performed to define the clinical difference between categorized groups. On multivariate analysis to examine the association of variables with OS, Cox proportional-hazard regression models were utilized to define covariate-adjusted hazard ratios (HR). All the statistical tests were two-sided with \( p < 0.05 \) considered to delineate statistical significance, which was performed using JMP® 13 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism software (GraphPad Software, La Jolla, CA, USA).

3. Results

The background of the cohort and clinical characteristics in the present study are shown in Figure 1 and Table 1. The mean age at diagnosis of CRPC was 73 years old. There were 66 of 254 patients (26.0%) who deceased during the follow-up. The median follow-up duration for patients who were alive (188 patients) and had died (66 patients) were 18 and 13 months, respectively. All the baseline backgrounds at the diagnosis of CRPC were comparable between the first-line treatment groups (AA and Enz) (Table 1), and there was no significant difference between AA and Enz in OS, TTPP from the initiation of the first-line treatment.

Table 1. Clinical Characteristics in 254 mCRPC patients treated with abiraterone: AA (n = 119) or enzalutamide: Enz (n = 135) at the first-line treatment.

| Characteristics                               | Total (n = 254) | 1st AA (n = 119) | 1st Enz (n = 135) | p-Value |
|-----------------------------------------------|----------------|-----------------|-----------------|---------|
| Age at CRPC (years)                           |                |                 |                 |         |
| mean ± SD                                     | 73.0 ± 0.4     | 72.9 ± 0.7      | 73.1 ± 0.6      | 0.880   |
| ≤70                                           | 94 (37.0)      | 40 (33.6)       | 54 (40.0)       | 0.292   |
| >70                                           | 160 (63.0)     | 79 (66.4)       | 81 (60.0)       |         |
| PSA (ng/ml) at diagnosis                      | 179 (40–710)   | 166 (45–692)    | 190 (33–715)    | 0.381   |
| median (IQR)                                  |                |                 |                 |         |
| Clinical stage at diagnosis                   | 131 (51.6)     | 55 (46.2)       | 76 (56.3)       | 0.108   |
| T2−T3                                        | 123 (48.4)     | 64 (53.8)       | 59 (43.7)       |         |
| T4                                            |                |                 |                 |         |
| Gleason sum score at diagnosis                | 86 (33.9)      | 39 (32.8)       | 47 (44.8)       | 0.660   |
| <9                                            | 168 (66.1)     | 80 (67.2)       | 88 (55.2)       |         |
| ≥9                                            |                |                 |                 |         |
| duration of ADT before CRPC (months)          |                |                 |                 |         |
| ≥12                                           | 180 (70.9)     | 78 (65.5)       | 102 (75.6)      | 0.079   |
| <12                                           | 74 (29.1)      | 41 (34.5)       | 33 (24.4)       |         |
| ECOG-PS at CRPC                               |                |                 |                 |         |
| 0                                             | 164 (64.6)     | 81 (68.1)       | 83 (61.5)       | 0.273   |
| ≥1                                            | 90 (35.4)      | 38 (31.9)       | 52 (38.5)       |         |
Cancers 2021, 13, x 5 of 13

Table 1. Cont.

| Characteristics               | Total (n = 254) | 1st AA (n = 119) | 1st Enz (n = 135) | p-Value |
|-------------------------------|----------------|-----------------|------------------|---------|
|                               | n              | %               | n               | %       | n       | %       |        |
| bone mets at CRPC             |                |                 |                  |         |         |         |        |
| –                             | 50             | 19.7            | 22               | 18.5    | 28      | 20.7    | 0.652  |
| +                             | 204            | 80.3            | 97               | 81.5    | 107     | 79.3    |
| lymph node mets at CRPC       |                |                 |                  |         |         |         |        |
| –                             | 135            | 53.1            | 64               | 53.8    | 71      | 52.6    | 0.849  |
| +                             | 119            | 46.9            | 55               | 46.2    | 64      | 47.4    |
| visceral mets at CRPC         |                |                 |                  |         |         |         |        |
| –                             | 215            | 84.6            | 101              | 84.9    | 114     | 84.4    | 0.924  |
| +                             | 39             | 15.4            | 18               | 15.1    | 21      | 15.6    |
| Laboratory data at CRPC       |                |                 |                  |         |         |         |        |
| median (IQR)                  |                |                 |                  |         |         |         |        |
| PSA (ng/mL)                   | 10.7 (3.2–31.1)| 9.5 (3.1–24.6)  | 11.1 (3.2–39.0)  | 0.188   |
| ALP (IU/L)                    | 252 (198–356)  | 256 (202–381)   | 247 (161–348)    | 0.194   |
| LDH (IU/L)                    | 201 (183–239)  | 199 (182–238)   | 201 (183–243)    | 0.350   |
| Hb (g/dL)                     | 12.6 (11.3–13.5)| 12.7 (11.4–13.5)| 12.6 (9.8–13.4)  | 0.457   |
| Median OS from the diagnosis  |                 |                 |                  |         |         |         |        |
| of CRPC (months)              | NR             | NR              | 45               | 0.325   |
| Median TTPP from the diagnosis of CRPC (months) | 11 | 12 | 11 | 0.514 |

mCRPC, metastatic castration-resistant prostate cancer; AA, abiraterone acetate; Enz, enzalutamide; ADT, androgen deprivation therapy; ECOG-PS, eastern cooperative oncology group performance status; mets, metastasis; PSA, prostate-specific antigen; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; Hb, hemoglobin; OS, overall survival; TTPP, time to PSA progression; SD, standard derivation; IQR, interquartile range; NR, not reached.

We first assessed the correlation of PSA changes between 4 and 12 weeks from the baseline. As shown in Figure 2, PSA changes at four weeks exhibited a significant positive correlation with those at 12 weeks from the initiation of the first-line treatment in patients treated with both AA (Spearman’s correlation coefficient: 0.650, 95%CI: 0.532–0.743, p < 0.0001) and Enz (Spearman’s correlation coefficient: 0.680, 95%CI: 0.577–0.761, p < 0.0001). We investigated the ROC curve to determine the optimal cut-off in PSA changes at four weeks of the treatment for the event of achieving >30% PSA decline (PSA30D) at 12 weeks. As shown in Figure 3, the Youden-index, the point maximizing the difference between the true-positive and false-positive rates across all possible cut-off values, identified the optimal cut-off value of PSA change from the baseline at approximately 30% (0.27) at four weeks of the treatment. Thus, we further explore the patient distribution according to the achievement of PSA30D at 4 and 12 weeks of the first-line treatment.

![Figure 2](image-url). Correlation of PSA changes between 4 and 12 weeks from the initiation of the first-line abiraterone acetate (AA: left panel) and enzalutamide (Enz: right panel). The axis indicates the ratio of PSA value, i.e., (at four weeks/at baseline: X-axis) and (at 12 weeks/at baseline: Y-axis).
We divided 254 mCRPC patients into two groups according to the achievement of PSA30D from the baseline. At four weeks of the treatment, 157 patients (61.8%) had PSA30D from the baseline. Thereafter, 177 patients (69.7%) achieved PSA30D at 12 weeks of the treatment. We next assessed a predictive impact of PSA30D from the baseline at 4 and 12 weeks of the treatment. In agreement with previous studies [22,28–32], the achievement of PSA30D at both 4 and 12 weeks were significantly correlated with an improved OS (4 weeks: \( p = 0.009 \), 12 weeks: \( p < 0.001 \): Figure 4a), TTPP (4 weeks: \( p < 0.001 \), 12 weeks: \( p < 0.001 \): Figure 4b). To further assess the predictive value of early PSA response, we conducted a multivariate analysis for OS from the initiation of the first-line treatments. A number of variables were found to be independent predictors for OS, including duration of ADT before CRPC (HR: 3.08, 95%CI: 1.67-5.74, \( p < 0.001 \)), ECOG-PS (HR: 3.63, 95%CI: 2.09-6.44, \( p < 0.001 \)), bone metastasis (HR: 4.08, 95%CI: 1.46-14.7, \( p = 0.005 \)), as well as PSA30D at four weeks (HR: 0.48, 95%CI: 0.28-0.84, \( p = 0.009 \)) (Table 2). These data indicated that the achievement of PSA30D as early as four weeks of the first-line ASIs potentially offers a predictive value for OS in mCRPC patients.

![Figure 3. Receiver operating characteristic (ROC) curves to determine the optimal cut-off in PSA changes at four weeks of the treatment for the event of achieving PSA30D at 12 weeks. The Youden-index, the point maximizing the difference between the true-positive and false-positive rates across all possible cut-off values, was indicated at * mark.](image-url)

![Figure 2. Correlation of PSA changes between 4 and 12 weeks from the initiation of the first-line ASIs.](image-url)

![Figure 4. Kaplan-Meier curves for overall survival (OS) (a) and time to PSA progression (TTPP) (b) from the initiation of the first-line ASIs. Each figure, patients were divided into two groups according to the achievement of >30% PSA decline (PSA30D) at 4 weeks or 12 weeks of the treatment.](image-url)
Table 2. Multivariate analysis for OS in 254 mCRPC patients treated with AA or Enz at the first-line treatment.

| Variables                              | Multivariate |
|----------------------------------------|--------------|
|                                        | HR (95% CI)  | p-Value   |
| Age at CRPC (years)                    | 0.82 (0.47–1.43) | 0.484     |
| ≤70/>70                                |              |           |
| Clinical stage at diagnosis            | 0.81 (0.45–1.45) | 0.485     |
| T2–T3/T4                               |              |           |
| Gleason sum score at diagnosis         | 1.04 (0.67–1.88) | 0.876     |
| <9/≥9                                  |              |           |
| duration of ADT before CRPC (months)   | 3.08 (1.67–5.74) | <0.001 *  |
| ≥12/<12                                | (2.09–6.44)  |           |
| ECOG-PS at CRPC                        | 3.63 (2.09–6.44) | <0.001 *  |
| 0/≥1                                   |              |           |
| bone mets at CRPC                      | 4.08 (1.46–14.70)  | 0.005 *   |
| −/+                                    |              |           |
| lymph node mets at CRPC                | 1.56 (0.91–2.67)  | 0.102     |
| −/+                                    |              |           |
| visceral mets at CRPC                  | 1.25 (0.62–2.36)  | 0.500     |
| −/+                                    |              |           |
| first-line treatment of CRPC           | 1.55 (0.88–2.77)  | 0.119     |
| AA/Enz                                 |              |           |
| >30% PSA decline (PSA30D) at four weeks| 0.48 (0.28–0.84)  | 0.009 *   |
| −/+                                    |              |           |

OS, overall survival; mCRPC, metastatic castration-resistant prostate cancer; AA, abiraterone acetate; Enz, enzalutamide; HR, hazard ratio; CI, confidence interval; ADT, androgen deprivation therapy; ECOG-PS, eastern cooperative oncology group performance status; mets, metastasis; PSA, prostate-specific antigen; * denotes $p < 0.05$.

To further investigate the clinical value of early PSA response for patients treated with ASIs at the first-line treatment, we stratified patients into four groups according to the achievement of PSA30D at 4 and 12 weeks (Table 3). Of 157 patients (61.8%) who had PSA30D at four weeks of the treatment, most patients ($n = 147$; 93.6%) were consistently offered PSA30D at 12 weeks. On the other hand, of 97 (38.2%) patients without achieving PSA30D at four weeks, 67 (69.1%) patients did not either achieve PSA30D at 12 weeks of the treatment, whereas 30 (30.9%) patients met the criteria for PSA30D at 12 weeks of the treatment.

Table 3. Patient distribution according to >30% PSA decline (PSA30D) at 4 and 12 weeks from the initiation of first-line treatment using ASIs (AA or Enz) in 254 mCRPC patients.

| Variables                              | At 12 Weeks |
|----------------------------------------|-------------|
|                                        | PSA30D (+) ($n = 177$, 69.3%) | PSA30D (−) ($n = 77$, 30.7%) |
| at 4 weeks                             | (n = 157, 61.8%) | 147 (57.9%) | 10 (3.9%) |
|                                       | (n = 97, 38.2%) | 30 (11.8%) | 67 (26.4%) |

PSA, prostate-specific antigen; ASIs, androgen signaling inhibitors; AA, abiraterone acetate, Enz, enzalutamide; mCRPC, metastatic castration-resistant prostate cancer.

To assess whether these four patient groups stratified by the achievement of PSA30D at 4 and 12 weeks exhibited distinct survival outcomes, we assessed OS in these four groups (Figure 5). Of 157 patients who achieved PSA30D at four weeks of the treatment, patients with achieving PAS30D at 12 weeks appeared to have longer OS than those without achieving PSA30D at 12 weeks (3 years OS rate: 70.5% vs. 41.6% in patients with and without PSA30D at 12 weeks, respectively). Of note, in 97 patients without achieving PSA30D at four weeks, OS in 30 patients (30.9%) who consequently achieved PSA30D at 12 weeks was significantly longer than that in 67 patients (69.1%) without PSA30D in both 4 and 12 weeks (3 years OS rate: 69.7% vs. 39.5% in patients with and without PSA30D at 12 weeks, respectively).
Although the early PSA decline (PSA30D) at four weeks using ASIs as the first-line treatment seemed to be a significant predictor for an improved OS, we noted that 30 of 97 (30.9%) patients, who did not achieve PSA30D at four weeks, but consequently achieved PSA30D at 12 weeks, had a comparable three years OS rate as favorable as 147 patients achieving PSA30D at both 4 and 12 weeks of the treatment (69.7% vs. 70.5% in former and latter, respectively, \( p = 0.642 \)), which prompted us to assess prognostic factors for OS specifically in patients not achieving PSA30D at four weeks of the treatment. To this end, we further performed multivariate analysis for OS in 97 patients who did not achieve PSA30D at four weeks (Table 4). This revealed that duration of ADT < 12 months (HR: 3.45, 95% CI: 1.36–9.25, \( p = 0.008 \)) and ECOG-PS \( \geq 9 \) (HR: 3.70, 95% CI: 1.13–11.47, \( p = 0.028 \)) were identified as independent predictors of shorter OS for mCRPC patients not achieving PSA30D at four weeks of the first-line ASIs.

Table 4. Multivariate analyses for OS in 97 mCRPC patients without >30% PSA decline (PSA30D) at four weeks of the first-line treatment using ASIs.

| Variables                                | HR (95% CI) | \( p \)-Value |
|------------------------------------------|-------------|---------------|
| Age at CRPC (years)                      |             |               |
| \( \leq 70 \) / >70                      | 1.18        | (0.49–2.70)   | 0.694 |
| Clinical stage at diagnosis              |             |               |
| T2–T3/T4                                 | 1.02        | (0.41–2.45)   | 0.951 |
| Gleason sum score at diagnosis           |             |               |
| \( <9 \) / \( \geq 9 \)                 | 0.70        | (0.27–1.89)   | 0.480 |
| duration of ADT before CRPC (months)     |             |               |
| \( \geq 12 \) / <12                      | 3.45        | (1.36–9.25)   | 0.008 *|
| ECOG-PS at CRPC                          |             |               |
| \( 0 \) / \( \geq 1 \)                  | 3.98        | (1.64–10.32)  | 0.002 *|
| bone mets at CRPC                        |             |               |
| \( –/+ \)                                | 3.66        | (0.80–28.81)  | 0.099 |
| lymph node mets at CRPC                  |             |               |
| \( –/+ \)                                | 1.11        | (0.46–2.66)   | 0.806 |
| visceral mets at CRPC                    |             |               |
| \( –/+ \)                                | 1.14        | (0.34–3.13)   | 0.810 |
| first-line treatment of CRPC             |             |               |
| AA/Enz                                  | 1.61        | (0.72–3.66)   | 0.241 |

OS, overall survival; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen; ASIs, androgen signaling inhibitors; HR, hazard ratio; CI, confidence interval; ADT, androgen deprivation therapy; ECOG-PS, eastern cooperative oncology group performance status; mets, metastasis; AA, abiraterone acetate; Enz, enzalutamide; * denotes \( p < 0.05 \).
4. Discussion

Precise evaluation of treatment responses for mCRPC is still challenging. Given the number of new agents approved by the FDA in mCRPC setting, identification of early or primary resistance to the treatment is of great value on clinical practice, allowing us to consider an early switch to the next agent and preventing unnecessary treatment that does not benefit for the patient outcome, as well as treatment-related toxicities. However, a recent report that inquired decision-making of clinical management for physicians treating mCRPC had revealed that, despite being considered an important bio-marker, 41.4% of the interviewed physicians disregard PSA changes before 12 weeks of the treatment, whereas the majority of physicians (90.5%) switched treatment based only on clinical progression [33]. This implies that the appropriate timing of next-line treatment is still controversial for mCRPC patients. There have been a number of studies showing that PSA30D after 12 weeks of the treatment is correlated with OS in mCRPC patients [34–36]. A recent randomized controlled trial for cabazitaxel (TAXYNERGY study) employed a PSA performance at 12 weeks as a criterion for treatment switch in their trial [37]. Nonetheless, prostate cancer working group 3 (PCWG3) criteria does not encourage treatment decision making based on early PSA changes within the first 12 weeks, since flare reactions of PSA occur in approximately a third of patients treated with taxanes [19–21]. On the other hand, the prognostic value of PSA30D at four weeks of the treatment using ASIs has been reported in several studies [22,28–32,38], whereas all those studies included the post-docetaxel population in their analysis. In the present study, we investigated the predictive value of early PSA response (>30% PSA decline: PSA30D) at four weeks of the first-line treatment using AA or Enz for mCRPC patients. The multivariate analysis for predicting OS exhibited PSA30D at four weeks as an independent predictor for a favorable OS. Despite the strong positive-correlation of PSA changes between 4 and 12 weeks of the first-line ASIs (Figure 2), 30 of 97 patients (30.9%) without PSA30D at four weeks consequently achieved PSA30D at 12 weeks (Table 3). Importantly, those 30 patients had a comparable OS as favorable as 147 patients achieving PSA30D at both 4 and 12 weeks of the first-line ASIs (3 years OS rate of 69.7% vs. 70.5% in 30 and 147 patients, respectively, \( p = 0.642 \)), which implies approximately a third (30 of 97) of patients, who were treated with ASIs as the first-line and did not have an early PSA response (PSA30D) at four weeks, still could benefit from continuing the first-line treatment. A recent report from an international collaborative study analyzing the early PSA response (PSA30D) at four weeks of ASIs included a population of post-docetaxel setting (53.2%) [22]. In their cohort, the proportion consequently achieving PSA30D at 12 weeks in patients without achieving PSA30D at four weeks was 22.0% (100 of 454 patients) compared to 30.9% (30 of 97 patients) in the present study. Unfortunately, survival outcomes in those patients (four groups stratified by the achievement of PSA30D at 4 and 12 weeks) were not exhibited in their report. In the present study, we sought to identify what variables discriminate the patient survival in 97 patients without achieving PSA30D at four weeks of the first-line ASIs by the multivariate analysis (Table 4). The duration of ADT before CRPC < 12 months (HR: 3.45, 95%CI: 1.36–9.25, \( p = 0.008 \)) and ECOG-PS >1 (HR: 3.98, 95%CI: 1.64–10.32, \( p = 0.002 \)) was identified as independent predictors of the shorter OS when no early PSA decline at four weeks was observed in mCRPC patients treated with ASIs as the first-line treatment. These data indicate a possibility of early treatment switch at four weeks of the first-line ASIs when not observing >30% PSA decline (PSA30D) at four weeks, particularly in patients with a modest effect of ADT and poor performance status.

The findings in the present study should be interpreted within several limitations. Firstly, this study was limited by its retrospective design that might have caused selection bias. Secondly, with being devoid of clinical records to define the treatment failure, we could not analyze the treatment outcomes from the second-line treatment, especially in comparing survival outcomes according to sequential therapy [39,40]. Thirdly, the dosage/adherence of the treatment, e.g., relative dose intensity, in individuals was not considered in the
present study. Finally, we could not consider biological markers for treatment outcomes, including ARV7 [41].

5. Conclusions

This study investigated the predictive value of PSA30D at four weeks of the first-line ASIs for mCRPC patients. PSA changes at four weeks from the baseline were positively correlated with those at 12 weeks. The achievement of PSA30D at four weeks was an independent predictor for OS. Of note, in patients without achieving PSA30D at four weeks (97 of 254 patients: 38.2%), an achievement of PSA30D at 12 weeks was eventually observed in 30.9% of those patients (30 of 97 patients). To identify the variables that discriminate the patient survival in 97 patients without achieving PSA30D at four weeks of the first-line treatment, a multivariate analysis was performed. Duration of ADT before CRPC < 12 months and ECOG-PS >1 were identified as independent predictors for shorter OS for those patients. These data collectively offer a concept of early treatment switch at four weeks of the first-line ASIs when not observing PSA30D at four weeks, particularly in patients with a modest effect of ADT and poor performance status. Large-scale and prospective studies are warranted to prove the result from the present study.

Author Contributions: Conceptualization, T.U.; Data curation, T.U., W.F. and K.T. (Kazuhiro Takahashi); Formal analysis, T.U., W.F., K.T. (Kazuki Nishimura), K.N. (Keita Nakamori), Y.F. and T.M.; Investigation, T.U., W.F., K.T. (Kazuo Takahashi), K.N. (Kazuki Nishimura), K.N. (Keita Nakamori), Y.F. and T.M.; Methodology, T.U.; Project administration, T.U., K.K., T.K., T.I., S.E. and H.A.; Resources, K.T. (Kohei Taniguchi), T.T. (Takuya Tsutsumi), T.T. (Takuya Tsujino), R.M. and Y.Y.; Validation, T.U., T.T. (Tomohito Tanaka) and H.U.; Software, T.U.; Supervision, T.U., K.K., T.K., T.I., S.E. and H.A.; Visualization, T.U.; Writing—Original draft, T.U., K.K., T.K., N.I., H.H., H.N., K.T. (Kiyoshi Takahara), T.I., S.E. and H.A.; Writing—Review & editing, T.U., K.K., T.K., T.I., S.E. and H.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Osaka Medical College (IRB number: RIN-750-2571 and Date of approval: 2020/01/24).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: This work was partially supported by Grant-in-Aid No. 19K18624 (Japan Society for the Promotion of Science: JSPS), the Uehara Memorial Foundation, the NOVARTIS Foundation (Japan) for the Promotion of Science, Japan Research Foundation for Clinical Pharmacology, Yamaguchi Endocrine Disease Research Foundation, and the Takeda Science Foundation 2018 in Japan.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [CrossRef] [PubMed]
2. Miller, K.D.; Nogueira, L.; Mariotto, A.B.; Rowland, J.H.; Yabroff, K.R.; Alfano, C.M.; Jemal, A.; Kramer, J.L.; Siegel, R.L. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 2019, 69, 363–385. [CrossRef] [PubMed]
3. Chakraborty, G.; Armenia, J.; Mazzu, Y.Z.; Nandakumar, S.; Stopsack, K.H.; Atiq, M.O.; Komura, K.; Jehane, L.; Hirani, R.; Chadalavada, K.; et al. Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clin. Cancer Res. 2020, 26, 2047–2064. [CrossRef] [PubMed]
4. Mazzu, Y.Z.; Armenia, J.; Chakraborty, G.; Yoshikawa, Y.; Coggins, S.A.; Nandakumar, S.; Gerke, T.A.; Pomerantz, M.M.; Qiu, X.; Zhao, H.; et al. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin. Cancer Res. 2019, 25, 4480–4492. [CrossRef] [PubMed]
5. Komura, K.; Yoshikawa, Y.; Shimamura, T.; Chakraborty, G.; Gerke, T.A.; Hinohara, K.; Chadalavada, K.; Jeong, S.H.; Armenia, J.; Du, S.Y.; et al. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J. Clin. Invest. 2018, 128, 2979–2995. [CrossRef]
6. Sun, T.; Du, S.Y.; Armenia, J.; Qu, F.; Fan, J.; Wang, X.; Fei, T.; Komura, K.; Liu, S.X.; Lee, G.M.; et al. Expression of IncRNA MIR22HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer. *Onco genesis* 2018, 7, 30. [CrossRef]

7. Komura, K.; Jeong, S.H.; Hinohara, K.; Qu, F.; Wang, X.; Hiraki, M.; Azuma, H.; Lee, G.S.; Kantoff, P.W.; Sweeney, C.J. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. *Proc. Natl. Acad. Sci. USA* 2016, 113, 6259–6264. [CrossRef]

8. De Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B.; Jr; Saad, F.; et al. Abiraterone and increased survival in metastatic prostate cancer. *N. Engl. J. Med.* 2011, 364, 1995–2005. [CrossRef]

9. Ryan, C.J.; Smith, M.R.; de Bono, J.S.; Molina, A.; Logothetis, C.J.; de Souza, P.; Fizazi, K.; Mainwaring, P.; Puilats, J.M.; Ng, S.; et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N. Engl. J. Med.* 2013, 368, 138–148. [CrossRef]

10. Scher, H.I.; Fizazi, K.; Saad, F.; Taplin, M.E.; Sternberg, C.N.; Miller, K.; de Wit, R.; Mulders, P.; Chi, K.N.; Shore, N.D.; et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N. Engl. J. Med.* 2012, 367, 1187–1197. [CrossRef]

11. Beer, T.M.; Armstrong, A.J.; Rathkopf, D.E.; Loriot, Y.; Sternberg, C.N.; Higano, C.S.; Iversen, P.; Bhattacharya, S.; Carles, J.; Chowdhury, S.; et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N. Engl. J. Med.* 2014, 371, 424–433. [CrossRef] [PubMed]

12. De Bono, J.S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J.P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M.J.; Shen, L.; et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. *Lancet* 2010, 376, 1147–1154. [CrossRef]

13. Parker, C.; Nilsson, S.; Heinrich, D.; Helle, S.I.; O’Sullivan, J.M.; Fossa, S.D.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N. Engl. J. Med.* 2013, 369, 213–223. [CrossRef] [PubMed]

14. Attard, G.; Parker, C.; Eles, R.A.; Schroder, F.; Tomlins, S.A.; Tannock, I.; Drake, C.G.; de Bono, J.S. Prostate cancer. *Lancet* 2016, 387, 70–82. [CrossRef]

15. Komura, K.; Sweeney, C.J.; Inamoto, T.; Iibu, N.; Azuma, H.; Kantoff, P.W. Current treatment strategies for advanced prostate cancer. *Int. J. Urol.* 2018, 25, 220–231. [CrossRef]

16. Uchimoto, T.; Komura, K.; Fujiwara, Y.; Saito, K.; Tanda, N.; Matsunaga, T.; Ichihashi, A.; Tsutsuji, T.; Yosikawa, Y.; et al. Prognostic impact of C-reactive protein–albumin ratio for the lethality in castration-resistant prostate cancer. *Med. Oncol.* 2019, 37, 9. [CrossRef]

17. Xu, X.S.; Ryan, C.J.; Stuyckens, K.; Smith, M.R.; Saad, F.; Griffin, T.W.; Park, Y.C.; Yu, M.K.; Vermeulen, A.; Poggesi, I.; et al. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. *Clin. Cancer Res.* 2015, 21, 3170–3177. [CrossRef]

18. Matsubara, N.; Chi, K.N.; Ozguroglu, M.; Rodriguez-Antolin, A.; Feyerabend, S.; Fein, L.; Alekseev, B.Y.; Sulur, G.; Protheroe, A.; Li, S.; et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. *Eur. Urol.* 2020, 77, 494–500. [CrossRef]

19. Scher, H.I.; Morris, M.J.; Stadler, W.M.; Higano, C.; Basch, E.; Fizazi, K.; Antonarakis, E.S.; Beer, T.M.; Carducci, M.A.; Chi, K.N.; et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *J. Clin. Oncol.* 2016, 34, 1402–1418. [CrossRef]

20. Berthold, D.R.; Pond, G.R.; Roessner, M.; de Wit, R.; Eisenberger, M.; Tannock, A.I.; Tax investigation. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. *Clin. Cancer Res.* 2008, 14, 2763–2767. [CrossRef]

21. Angelergues, A.; Maillet, D.; Flechon, A.; Ozguroglu, M.; Mercier, F.; Guillot, A.; Le Moulec, S.; Gravis, G.; Beuzeboc, P.; Massard, C.; et al. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. *Eur. J. Cancer* 2014, 50, 1602–1609. [CrossRef] [PubMed]

22. Rescigno, P.; Dolling, D.; Conteduca, V.; Rediti, M.; Bianchini, D.; Lolli, C.; Ong, M.; Li, H.; Omlin, A.G.; Schmid, S.; et al. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. *Eur. Urol. Oncol.* 2020, 3, 176–182. [CrossRef] [PubMed]

23. Gandevia, B.; Tovell, A. Declaration of Helsinki. *Med. J. Aust.* 1964, 2, 320–321. [PubMed]

24. Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. *J. Clin. Oncol.* 2008, 26, 1148–1159. [CrossRef] [PubMed]

25. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur. J. Cancer 2009, 45, 228–247. [CrossRef]

26. Youden, W.J. Index for rating diagnostic tests. *Cancer* 1950, 3, 32–35. [CrossRef]

27. Unal, I. Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach. *Comput. Math. Methods Med.* 2017, 2017, 3762651. [CrossRef]

28. Rescigno, P.; Lorente, D.; Bianchini, D.; Ferraldeschi, R.; Kolinsky, M.P.; Sideris, S.; Zafeiriou, Z.; Sumanasuriya, S.; Smith, A.D.; Mehra, N.; et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Prostate Cancer. *Eur. Urol.* 2016, 70, 724–731. [CrossRef]
29. Brasso, K.; Thomsen, F.B.; Schrader, A.J.; Schmid, S.C.; Lorente, D.; Retz, M.; Merseburger, A.S.; von Klot, C.A.; Boegemann, M.; de Bono, J. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Ablative Radiotherapy: A Multicentre Analysis. Eur. Urol. 2015, 68, 317–324. [CrossRef]

30. Facchini, G.; Caffo, O.; Ortega, C.; D’Aniello, C.; Di Napoli, M.; Cecere, S.C.; Della Pepa, C.; Crispo, A.; Maines, F.; Ruatta, F.; et al. Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. Front. Pharmacol. 2016, 7, 123. [CrossRef]

31. Fuereka, A.; Bacich, G.; Patrikidou, A.; Albiges, L.; Massard, C.; Di Palma, M.; Escudier, B.; Fizazi, K.; Loriot, Y. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. Eur. J. Cancer 2016, 68, 317–324. [CrossRef]

32. Kato, H.; Furuya, Y.; Miyazawa, Y.; Miyao, T.; Saito, T.; Nomura, M.; Sekine, Y.; Koike, H.; Matsu, H.; Shibata, Y.; et al. Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. Anticancer. Res. 2016, 36, 6141–6149. [CrossRef] [PubMed]

33. Lorente, D.; Ravi, P.; Mehra, N.; Pezaro, C.; Omlin, A.; Gilmour, A.; Miranda, M.; Rescigno, P.; Kolinsky, M.; Porta, N.; et al. Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. Eur. Urol. Focus 2018, 4, 235–244. [CrossRef] [PubMed]

34. Sridhara, R.; Eisenberger, M.A.; Sinibaldi, V.J.; Reyno, L.M.; Egorin, M.J. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J. Clin. Oncol. 1995, 13, 2944–2953. [CrossRef]

35. Hussain, M.; Goldman, B.; Tangen, C.; Higano, C.S.; Petrylak, D.P.; Wilding, G.; Akdas, A.M.; Small, E.J.; Donnelly, B.J.; Sundram, S.K.; et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 2009, 27, 2450–2456. [CrossRef]

36. Petrylak, D.P.; Anker, D.P.; Jiang, C.S.; Tangen, C.M.; Hussain, M.H.; Lara, P.N., Jr.; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Kohli, M.; et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 2006, 98, 516–521. [CrossRef]

37. Antonarakis, E.S.; Tagawa, S.T.; Galletti, G.; Worroll, D.; Ballman, K.; Vanhuyse, M.; Sonpavde, G.; North, S.; Alban, C.; Tsao, C.K.; et al. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Velecept Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer. J. Clin. Oncol. 2017, 35, 3181–3188. [CrossRef]

38. Schiff, J.P.; Cotogno, P.; Feibus, A.; Steinwald, P.; Ledet, E.; Lewis, B.; Sartor, O. Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. BMC Cancer 2019, 19, 524. [CrossRef]

39. Okita, K.; Hatakeyama, S.; Naito, S.; Takahashi, M.; Sakurai, T.; Kawamura, S.; Hoshi, S.; Ishida, M.; Kawaguchi, T.; Ishidoya, S.; et al. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study. Clin. Genitourin. Cancer 2020, 18, e103–e111. [CrossRef]

40. Mori, K.; Miura, N.; Mostafaei, H.; Qahal, F.; Sari Motlagh, R.; Pradere, B.; Kimura, S.; Kimura, T.; Egawa, S.; Briganti, A.; et al. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2020, 23, 539–548. [CrossRef]

41. Qu, F.; Xie, W.; Nakabayashi, M.; Zhang, H.; Jeong, S.H.; Wang, X.; Komura, K.; Sweeney, C.J.; Sartor, O.; Lee, G.M.; et al. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin. Cancer Res. 2017, 23, 726–734. [CrossRef] [PubMed]